Results 1 to 10 of about 16,400 (171)

HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure. [PDF]

Viruses, 2022
Despite the availability of effective vaccines and antiviral therapy over the past two to three decades, chronic hepatitis B virus (HBV) infection remains a major global health threat as a leading cause of cirrhosis and liver cancer. Functional HBV cure defined as hepatitis B surface antigen (HBsAg) loss and undetectable serum HBV DNA is associated ...
Moini M, Fung S.
europepmc   +7 more sources

Sustained Liver HBsAg Loss and Clonal T- and B-Cell Expansion upon Therapeutic DNA Vaccination Require Low HBsAg Levels. [PDF]

Vaccines (Basel), 2023
Abstract Background & Aims Suppression of HBV DNA, inhibition of HBsAg production and therapeutic vaccination to reverse HBV-specific T-cell exhaustion in chronic HBV patients are likely required to achieve functional cure.
Conceição-Neto N, Pierson W, Vacca M, Beyens M, De Clerck B, Aerts L, Voeten B, De Pooter D, Verschueren L, Dockx K, Vandenberk M, De Troyer E, Verwilt K, Van Hove C, Verslegers M, Bosseler L, Crabbe M, Krishna V, Nájera I, Van Gulck E.   +19 more
europepmc   +5 more sources

Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels [PDF]

Journal of Hepatology, 2022
Background & Aims: Nucleo(s)tide analogue (NUC) withdrawal may result in HBsAg clearance in a subset of patients. However, predictors of HBsAg loss after NUC withdrawal remain ill-defined.
Milan J Sonneveld, Sylvia M Brakenhoff, Apichat Kaewdech   +2 more
exaly   +9 more sources

Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation. [PDF]

BMC Gastroenterol, 2023
Abstract Background Since hepatitis B surface antigen (HBsAg) loss is rarely achieved with nucleos(t)ide analog (NA) treatment, most patients require life-long NA treatment. Previous studies have shown that some patients remain virologically responsive even after NA cessation. However, there is
Xie Y, Li M, Ou X, Zheng S, Gao Y, Xu X, Yang Y, Ma A, Li J, Nan Y, Zheng H, Liu J, Wei L, Feng B.   +13 more
europepmc   +4 more sources

Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss. [PDF]

Virol J
It is unclear whether nucleos(t)ide analogs (NUCs) continuation provides clinical benefits following HBsAg seroclearance with pegylated interferon (PEG-IFN)-based therapy. This study aims to investigate the role of NUCs continuation in HBsAg seroreversion.Patients who experienced serum HBsAg loss after PEG-IFN-based therapy were enrolled and followed ...
Gao N, Wu H, Li B, Yu H, Wu L, Zhang J, Zhang N, Lin B, Zhao Q, Gao Z.   +9 more
europepmc   +4 more sources

Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a. [PDF]

Virol Sin, 2021
Hepatitis B surface antigen (HBsAg) loss is an ideal treatment endpoint for patients with chronic hepatitis B (CHB). We investigated the predictive value of on-treatment HBsAg levels for HBsAg loss in hepatitis B e antigen (HBeAg)-negative CHB patients who received 120-week PEG-IFNα-2a treatment.
Li M, Zhang L, Lu Y, Chen Q, Lu H, Sun F, Zeng Z, Wan G, Zhao L, Xie Y.   +9 more
europepmc   +4 more sources

Hepatitis B Surface Antigen Loss and Improved Clinical Outcomes in US Individuals With Chronic Hepatitis B Virus Infection. [PDF]

J Viral Hepat
ABSTRACT Hepatitis B surface antigen (HBsAg) loss is associated with improved clinical outcomes in patients with chronic hepatitis B virus (HBV) infection based on studies predominantly in Asian populations. We assessed real‐world associations between HBsAg loss and long‐term clinical outcomes in a diverse US population with chronic HBV infection. This
Drysdale M, Chang R, Wang S, Coutinho A, Gielen V, Man T, Song R, Duh MS, Khalili M, Theodore D.   +9 more
europepmc   +2 more sources

Baseline HBsAg quantitative and CD4 T cell counts are associated with HBsAg loss in people living with HIV/HBV coinfection after combined antiretroviral therapy [PDF]

Frontiers in Cellular and Infection Microbiology
Muye Xia, Jie Peng
exaly   +2 more sources

Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C, or nonalcoholic steatohepatitis

Hepatology, EarlyView., 2022
Adaptive mitochondrial mechanisms allow mitochondrial resilience and prevent the worsening of fibrosis, while deregulation of these mechanisms promotes the progression from no/minimal‐mild (F0‐F2) fibrosis to advanced fibrosis and cirrhosis (F3‐F4). Abstract Background and Aims Hepatitis B virus (HBV) infection causes oxidative stress (OS) and alters ...
Dimitri Loureiro, Issam Tout, Stéphanie Narguet, Cheikh Mohamed Bed, Morgane Roinard, Ahmad Sleiman, Nathalie Boyer, Nathalie Pons‐Kerjean, Corinne Castelnau, Nathalie Giuly, Dorothy Tonui, Vassili Soumelis, Jamel El Benna, Patrick Soussan, Richard Moreau, Valérie Paradis, Abdellah Mansouri, Tarik Asselah   +17 more
wiley   +1 more source

Interferon-α could induce liver steatosis to promote HBsAg loss by increasing triglyceride level [PDF]

Heliyon
Zhaoxia Hu, Bingliang Lin, Zhi-Liang Gao   +2 more
exaly   +2 more sources